These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34439779)

  • 1. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J; Kamijo T
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.
    Yu EY; Cheung IY; Feng Y; Rabie MO; Roboz GJ; Guzman ML; Cheung NV; Lue NF
    Neoplasia; 2019 Jul; 21(7):689-701. PubMed ID: 31128432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
    Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
    Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.
    Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K
    Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
    Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
    Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A
    Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
    Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
    J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.
    Zhao M; Guan Z; Gong L; Liu F; Gu W; Liu L; Jiang K; Cai J; Feng C; Kuick CH; Chang KTE; Wang J; Tang H; Yin M; Mao J
    Pathology; 2023 Dec; 55(7):958-965. PubMed ID: 37741703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Loss of
    Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
    Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres.
    Graham MK; Xu B; Davis C; Meeker AK; Heaphy CM; Yegnasubramanian S; Dyer MA; Zeineldin M
    Cancer Res Commun; 2024 Jun; 4(6):1533-1547. PubMed ID: 38837897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.
    Duan XF; Zhao Q
    J Pediatr Hematol Oncol; 2018 Jan; 40(1):1-6. PubMed ID: 28452859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof.
    Claude E; Decottignies A
    Curr Opin Genet Dev; 2020 Feb; 60():1-8. PubMed ID: 32114293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
    George SL; Parmar V; Lorenzi F; Marshall LV; Jamin Y; Poon E; Angelini P; Chesler L
    J Exp Clin Cancer Res; 2020 May; 39(1):78. PubMed ID: 32375866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
    Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
    Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere maintenance is pivotal for high-risk neuroblastoma.
    Hertwig F; Peifer M; Fischer M
    Cell Cycle; 2016; 15(3):311-2. PubMed ID: 26653081
    [No Abstract]   [Full Text] [Related]  

  • 18. MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
    Zeineldin M; Federico S; Chen X; Fan Y; Xu B; Stewart E; Zhou X; Jeon J; Griffiths L; Nguyen R; Norrie J; Easton J; Mulder H; Yergeau D; Liu Y; Wu J; Van Ryn C; Naranjo A; Hogarty MD; Kamiński MM; Valentine M; Pruett-Miller SM; Pappo A; Zhang J; Clay MR; Bahrami A; Vogel P; Lee S; Shelat A; Sarthy JF; Meers MP; George RE; Mardis ER; Wilson RK; Henikoff S; Downing JR; Dyer MA
    Nat Commun; 2020 Feb; 11(1):913. PubMed ID: 32060267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
    Zhong ZY; Shi BJ; Zhou H; Wang WB
    J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
    Farooqi AS; Dagg RA; Choi LM; Shay JW; Reynolds CP; Lau LM
    J Neurooncol; 2014 Aug; 119(1):17-26. PubMed ID: 24792489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.